Ivabradin Axiromed (Ivabradine)

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, the pacemaker of the heart. This inhibition slows the spontaneous depolarisation of pacemaker cells, leading to a reduction in resting heart rate without affecting contractility or blood pressure, thereby improving myocardial oxygen supply‑demand balance.

The exact dose of Ivabradin Axiomed is determined by the prescribing clinician based on the individual’s clinical condition, heart‑rate targets, and tolerance. Physicians typically start with a low dose and may titrate upward, but the specific regimen should always follow the prescriber’s instructions.

Safety data for ivabradine in pregnancy and lactation are limited. It is classified as contraindicated or to be used only when the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Ivabradin Axiomed, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative for heart‑rate reduction in angina and heart failure is the beta‑blocker class. Unlike beta‑blockers, ivabradine lowers heart rate without affecting myocardial contractility or blood pressure, making it useful when beta‑blockers are contraindicated or not tolerated. However, beta‑blockers also provide anti‑arrhythmic and anti‑ischemic benefits that ivabradine does not.

Store Ivabradin Axiomed at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure the packaging remains sealed until use. Do not store in a refrigerator or freezer.

Ivabradin Axiomed is taken orally, usually with a glass of water. The tablets are swallowed whole and should be taken at the same times each day as directed by the prescriber. Food does not significantly affect absorption, but patients should follow any specific timing instructions given by their clinician.

The most serious adverse events include symptomatic severe bradycardia, syncope, atrioventricular block, and worsening heart failure. Patients should be educated to report any episodes of fainting, unusually slow heart rate, or sudden worsening of heart‑failure symptoms such as increased shortness of breath or swelling.

Ivabradin Axiomed should be avoided in patients with a resting heart rate below 60 bpm, those with severe hepatic impairment, patients dependent on pacemakers, and individuals taking strong CYP3A4 inhibitors without dose adjustment. It is also contraindicated in patients with acute decompensated heart failure or unstable angina.